Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
Healthcare
$0.90 +3.01%
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
52W Low $1.07High $6.18
Volume 1.45M
Average 2.13M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$33.35M
FY 2025 · Annual
Investing Cash Flow
$47.74M
FY 2025 · Annual
Financing Cash Flow
$1.12M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.11M | 8.29M | 5.75M | 7.97M | 6.09M |
| Change in Working Capital | 7.44M | (3.44M) | 861.18K | 5.91M | (5.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 638.06K | (886.08K) | 1.2M | (1.16M) | (21.99K) |
| Other Working Capital | 6.8M | (2.56M) | (343.25K) | 7.07M | (5.16M) |
| Other Non-Cash Items | 409.47K | 283.91K | 339.65K | (1.49M) | (664.43K) |
| Operating Cash Flow | (42.56M) | (56.64M) | (30.33M) | (43.21M) | (33.35M) |
| Capital Expenditures | (7.81K) | (16.32K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 16.32K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (92.94M) | 0 | (96.92M) | (40.26M) |
| Sales of Investments | 0 | 63M | 30M | 52M | 88M |
| Other Investing Activities | 0 | (16.32K) | 0 | 0 | 0 |
| Investing Cash Flow | (7.81K) | (29.95M) | 30M | (44.92M) | 47.74M |
| Debt Repayment | 0 | 0 | (1.04M) | (292.5K) | 0 |
| Common Stock Issued | 189.81M | 1.22M | 305.23K | 121.08K | 1.12M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.68M | 0 | (532.95K) | 0 | (444) |
| Financing Cash Flow | 194.5M | 1.22M | (1.27M) | (171.42K) | 1.12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.93M | (85.37M) | (1.6M) | (88.3M) | 15.51M |
| Free Cash Flow | (42.56M) | (56.65M) | (30.33M) | (43.21M) | (33.35M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$33.8M
+ D&A$252.0K
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
- Working Capital-$5.2M
- Other Non-Cash-$664.4K
= Operating Cash Flow-$33.3M
- Capex$0
= Free Cash Flow-$33.3M
Analysis
FY2025 free cash flow is -$33.3M. FCF conversion is 98.5% of net income. Operating cash flow was -$33.3M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Aug 12, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 | |
| 8-K | Current report | Jul 30, 2026 | |
| SC 13G/A | SC 13G/A filing | Jul 27, 2026 | |
| 8-K | Current report | Jul 15, 2026 |
Does ALDX generate free cash flow?
Aldeyra Therapeutics, Inc. (ALDX) generated -$33.35M of free cash flow in fiscal 2025.
How much operating cash flow does ALDX produce?
Operating cash flow was -$33.35M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.